Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: A randomized, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 75, Issue 10, 2014, Pages 1062-1068

  Gao, Keming ^a   Wu, Renrong ^a,b   Kemp, David E ^a   Chen, Jun ^a,c   Karberg, Elizabeth ^a   Conroy, Carla ^a   Chan, Philip ^a   Ren, Ming ^a   Serrano, Mary Beth ^a   Ganocy, Stephen J ^a   Calabrese, Joseph R ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; LITHIUM SALT; MOOD STABILIZER; PLACEBO; QUETIAPINE; VALPROATE SEMISODIUM; VALPROIC ACID; DELAYED RELEASE FORMULATION; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; EFFECT SIZE; FEMALE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; ACUTE DISEASE; ANXIETY DISORDERS; BIPOLAR DISORDER; DELAYED RELEASE FORMULATION; DRUG POTENTIATION; MIDDLE AGED; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BIPOLAR DISORDER; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME;

EID: 84921893876     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.13m08847     Document Type: Article

References (48)

1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543-552. doi:10.101/archpsyc.64.5.543 PubMed
2. Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 patients in the systematic treatment enhancement program for bipolar disorder (STEP-BP). Am J Psychiatry. 2004;161(12):222-229. doi:10.176/api.ajp.161.12.2
3. Gao K, Verduin ML, Kemp DE, et al. Clinical correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: a subtype comparison from baseline data of 2 randomized, placebocontrolled trials. J Clin Psychiatry. 2008;69(7):1057-1063. doi:10.408/JCP.v69n0703 PubMed
4. Gao K, Wang Z, Chen J, et al. Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? role of QIDS-16-SR total score in predicting number of Axis I comorbidity. J Affect Disord. 2013;148(2-3):256-264. doi:10.1016/j.jad.2012.12.04 PubMed
5. Frank E, Cyranowski JM, Rucci P, et al. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen Psychiatry. 2002;59(10):905-911. doi:10.101/archpsyc.59.10.905 PubMed
6. Schurhoff F, Bellivier F, Jouvent R, et al. Early and late onset bipolar disorders: two different forms of manic-depressive illness? J Affect Disord. 2000;58(3):215-221. doi:10.1016/S0165-0327(9)01-1 PubMed
7. Perlis RH, Miyahara S, Marangell LB, et al; STEP-BD Investigators. Longterm implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2004;55(9):875-881. doi:10.1016/j.biopsych.204.01.02 PubMed
8. Simon NM, Otto MW, Weiss RD, et al; STEP-BD Investigators. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004;24(5):512-520. doi:10.1097/01.jcp.013872.40515.70 PubMed
9. Schaffer A, McIntosh D, Goldstein BI, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012;24(1):6-22. PubMed
10. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163(2): 217-224. doi:10.176/api.ajp.163.2.217 PubMed
11. Chen J, Fang Y, Kemp DE, et al. Switching to hypomania and mania: differential neurochemical, neuropsychological, and pharmacologic triggers and their mechanisms. Curr Psychiatry Rep. 2010;12(6):512-521. doi:10.107/s1920-010-0157-z PubMed
12. Wu R, Gao K, Calabrese JR, et al. Treatment induced mood instability: treatment-emergent affective switches and cycle acceleration. In: Yildiz A, Nemeroff C, Ruiz P, eds. Bipolar Disorder: Millennium Update. New York, NY: Oxford University Press; in press.
13. Brunette MF, Noordsy DL, Xie H, et al. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv. 2003;54(10):1395-1401. doi:10.176/api.ps.54.10.1395 PubMed
14. Gao K, Muzina D, Gajwani P, et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006;67(9):1327-1340. doi:10.408/JCP.v67n0902 PubMed
15. Gao K, Sheehan DV, Calabrese JR. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother. 2009;9(8):1147-1158. doi:10.1586/ern.09.37 PubMed
16. Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder: data from a randomized, double-blind, placebo-and active-controlled study. Int J Neuropsychopharmacol. 2010;13(3):305-320. doi:10.1017/S1461457090423 PubMed
17. Khan A, Joyce M, Atkinson S, et al. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011;31(4):418-428. doi:10.1097/JCP.0b013e31824864d PubMed
18. Merideth C, Cutler AJ, She F, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and activecontrolled study. Int Clin Psychopharmacol. 2012;27(1):40-54. doi:10.1097/YIC.0b013e32834d9f49 PubMed
19. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360. doi:10.176/api.ajp.162.7.1351 PubMed
20. Thase ME, Macfadden W, Weisler RH, et al; BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600-609. doi:10.1097/01.jcp.0248603.76231.b7 PubMed
21. Young AH, McElroy SL, Bauer M, et al; EMBOLDEN I (Trial 001) Investigators. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71(2):150-162. doi:10.408/JCP.08m0495gre PubMed
22. McElroy SL, Weisler RH, Chang W, et al; EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163-174. doi:10.408/JCP.08m04942gre PubMed
23. Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121(1-2):106-115. doi:10.1016/j.jad.209.10.07 PubMed
24. Sheehan DV, Harnett-Sheehan K, Hidalgo RB, et al. Randomized, placebocontrolled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J Affect Disord. 2013;145(1):83-94. doi:10.1016/j.jad.2012.07.016 PubMed
25. Sheehan DV, McElroy SL, Harnett-Sheehan K, et al. Randomized, placebocontrolled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord. 2009;115(3):376-385. doi:10.1016/j.jad.208.10.05 PubMed
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
27. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55. doi:10.1/j.204-8341.1959.tb0467.x PubMed
28. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435. doi:10.192/bjp.13.5.429 PubMed
29. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. PubMed
30. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Patient Version. Washington, DC: American Psychiatric Press; 1997.
31. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-171. doi:10.1016/S0165-1781(97)0123-6 PubMed
32. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and selfreport (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. doi:10.1016/S06-323(02)0186-8 PubMed
33. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993; 29(2):321-326. PubMed
34. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(s212):11-19. doi:10.1/j.160-047.1970.tb0206.x PubMed
35. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676. doi:10.192/bjp.154.5.672 PubMed
36. Wisniewski SR, Rush AJ, Balasubramani GK, et al; STARD Investigators. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12(2):71-79. doi:10.1097/0131746-206030-02 PubMed
37. Cohen LS. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Erlbaum; 1988.
38. Stedman M, Pettinati HM, Brown ES, et al. A double-blind, placebocontrolled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol Clin Exp Res. 2010;34(10):1822-1831. doi:10.1/j.1530-027.2010.01270.x PubMed
39. Salloum IM, Cornelius JR, Daley DC, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a doubleblind placebo-controlled study. Arch Gen Psychiatry. 2005;62(1):37-45. doi:10.101/archpsyc.62.1.37 PubMed
40. Brown ES, Sunderajan P, Hu LT, et al. A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence. Neuropsychopharmacology. 2012;37(11):2347-2354. doi:10.1038/np.2012.90 PubMed
41. Tolliver BK, Desantis SM, Brown DG, et al. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2012;14(1):54-63. doi:10.1/j.139-5618.201.0973.x PubMed
42. Wang Z, Gao K, Kemp DE, et al. Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebocontrolled pilot study. Psychopharmacol Bull. 2010;43(4):5-21. PubMed
43. Gaudiano BA, Miller IW. Anxiety disorder comorbidity in Bipolar I Disorder: relationship to depression severity and treatment outcome. Depress Anxiety. 2005;21(2):71-77. doi:10.102/da.2053 PubMed
44. Tohen M, Calabrese J, Vieta E, et al. Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord. 2007;104(1-3): 137-146. doi:10.1016/j.jad.207.03.014 PubMed
45. Deckersbach T, Peters AT, Sylvia L, et al. Do comorbid anxiety disorders moderate the effects of psychotherapy for bipolar disorder? results from STEP-BD [published online ahead of print September 30, 2013]. Am J Psychiatry. doi:10.176/api.ajp.2013.1302025 PubMed
46. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A. 2003;100(24):14293-14296. doi:10.1073/pnas.23612610 PubMed
47. Post RM, Leverich GS, Altshuler LL, et al. Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany. Int Clin Psychopharmacol. 2011;26(2):96-106. doi:10.1097/YIC.0b013e3283409419 PubMed
48. Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? a systematic review for bipolar disorders. Bipolar Disord. 2005;7(5):404-417. doi:10.1/j.139-5618.205.024.x PubMed